



Biolux Research Announces Agreement with Citagenix for Exclusive Distribution of the OsseoPulse™ Bone Regeneration System in Canada.

VANCOUVER, B.C., CANADA – July 24, 2008 – Biolux Research Ltd. announced today that it has signed a new distribution agreement with Citagenix Inc. to commercialize the OsseoPulse™ Bone Regeneration System in Canada. The agreement provides exclusivity and a long term commitment necessary to introduce the new product to the Canadian dental market.

Uwe Tritthardt, President and CEO of Citagenix states that “the introduction of this cutting edge technology is a first and Citagenix is proud to be involved in marketing this innovative and novel approach to accelerating bone regeneration explicitly in the dental arena. OsseoPulse™ meets that pressing need for rapid bone healing in dental implantology. Furthermore, the addition of OsseoPulse™ represents an expansion of our regeneration product line in keeping with our mission of providing innovative medical devices to meet the needs of our clinicians.”

“We are excited to have partnered with Citagenix, as they are an outstanding distribution company in the dental space for regeneration products and solutions. They have excellent coverage of the 6,000 plus dentists and other specialists currently doing dental implants in Canada, and we feel that their consultative approach to selling through a focused, direct sales team will be successful in introducing our new product to the market,” states Kevin Strange, President and CEO of Biolux. “We look forward to working together to put the OsseoPulse™ on the market this Fall, and to a very promising relationship with Citagenix.”

The OsseoPulse™ has already received a Health Canada Medical Device Licence, and Biolux is currently establishing production of initial inventory of product to support market launch later in 2008.

About Biolux Research

Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research and is well positioned to release its OsseoPulse™ system to the marketplace in 2008. Its proprietary, patent pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

About Citagenix

Founded in 1997 in Montreal, Citagenix Inc. has become the largest source of knowledge and experience in the Canadian medical device industry when it comes to dental bone regeneration. They are known as a valuable reference and resource for bone grafting clinicians. Citagenix is a fully integrated innovative medical device company led by a highly experienced senior management and advisory team. They successfully commercialize their dental products through direct sales in Canada. It is their strategy to focus on developing or acquiring and commercializing new and novel medical devices with significant commercial potential, strong social and economic benefits, targeted at demand driven markets. www.citagenix.com.

For More Information:

Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com